Potential drug leads targeting IL-6, the IL-6 receptor, or Janus kinase (JAK)–signal transducer have been FDA approved for the treatment of inflammatory conditions or myeloproliferative neoplasms and are being further evaluated in patients with haematopoietic malignancies and in those with solid tumours (Johnson et al. 2018). This evidence concerns the gene IL6 and myeloproliferative disorder.